The purpose of this review was to identify and synthesise the existing evidence on effectiveness of interventions targeting people who inject drugs at two stages of the care cascade: linkage to care and adherence to treatment of HIV, hepatitis B/C and TB.
This report documents the process and outcome of the assessment and translation of the evidence into guidance recommendations on linkage to care and/or adherence to treatment for HCV, HIV and TB for the ECDC technical report, ‘A systematic literature review of interventions to increase linkage to care and adherence to treatment for hepatitis B and C, HIV and tuberculosis among people who inject drugs’.
More than 35 000 people die from antimicrobial-resistant infections in the EU/EEA each year, according to estimates presented in a new report released today. The estimated number of deaths in the report examines the years 2016-2020 and shows an increase from previous estimates. The health impact of antimicrobial resistance (AMR) is comparable to that of influenza, tuberculosis and HIV/AIDS combined.
This issue of the ECDC Communicable Disease Threats Report (CDTR) covers the period 30 October-5 November 2022 and includes updates on chikungunya, dengue, COVID-19, increase in hepatitis cases in children, monkeypox, West Nile virus, Ebola virus disease due to Sudan ebolavirus, and seasonal influenza.
This issue of the ECDC Communicable Disease Threats Report (CDTR) covers the period 2-8 October 2022 and includes updates on avian influenza, COVID-19, dengue, Ebola, invasive meningococcal disease, West Nile Virus, MERS-CoV, monkeypox, and hepatitis.
Clusters and outbreaks of hepatitis A virus (HAV) genotype IB with four unique but closely related HAV sequences have been reported in six European Union (EU) countries and in the United Kingdom (UK).